In June 2026 the MHRA approved oral semaglutide, marketed as the Wegovy pill , the first oral GLP-1 receptor agonist licensed in the UK for weight management (distinct from Rybelsus, a lower-dose oral semaglutide licensed for type 2 diabetes)
This study aims to evaluate the impact of GLP-1 on nicotine cravings, exploring their utilization and the subsequent changes in smoking behaviour and user perceptions
This is also where most of the controversy lies: Injections: This is the fastest-acting and most potent route, but it carries serious risks including allergic reactions, infections, kidney or thyroid damage, toxicity and ochronosis
We are constantly learning why bariatric surgery is so very effective on both weight and the disease trajectory, and we can use this knowledge to develop future treatments for people with type 2 diabetes and obesity, says Jens Juul Holst
We do not promise a specific number on the scale or a fixed result from any hormone, and where the science is still early, like NAD+, we say so rather than oversell it